Celldex Therapeutics, Inc. — Director's Dealing 2008

Mar 11, 2008

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07

Reporting Person: LIPTON KAREN SHOOS (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2008-03-07	Non-Qualified Stock Option	$8.16	A	17728	Acquired	2015-03-07	Common Stock (17728)	Direct

Footnotes

F1: This option was granted for 212,739 shares at an exercise price of $0.68 per share, but was adjusted to reflect the one-for-twelve reverse stock split that occurred on March 7, 2008.

F2: 78,500 options granted under the AVANT 1999 Stock Option and Incentive Plan were cancelled according to their terms for no consideration on March 7, 2008.